Monographie - Tacrolimus - Stabilis 4.0

Poslední aktualizace :
14/02/2025

Imunosupresantas

Tacrolimus

Geriamas tirpalas

Akių lašai

Įpurškimas

Stabilumas farmacinių preparatų

Mišinių stabilumas

Stabilumą lemiantys veiksniai

Suderinamumas

Bibliografija

pdf

Cheminė sandara

Geriamas tirpalas

Bibliografija

Geriamas tirpalas

Bibliografija : Tacrolimus

	tipas	leidinys
2436	Žurnalas	Jacobson PA, Johnson CE, West NJ, Foster JA. Stability of tacrolimus in an extemporaneously compounded oral liquid Am J Health-Syst Pharm 1997 ; 54: 178-180.
2789	Žurnalas	Elefante A, Muindi J, West K, Dunford L, Abel S, Paplham P, Brown K, Hahn T, Padmanabhan S, Battiwalla M, McCarthy PL. Long-term stability of a patient-convenient 1mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplantation 2006 ; 37, 8: 781-784.
3846	Žurnalas	Polonini HC, Silva SL, Cunha CN, Brand?o MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie 2016 71: 185?191.
3946	Žurnalas	Friciu M, Zaraa S, Leclair G. Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes Can J Hosp Pharm 2017 ; 70,1 :51-53.
4177	Žurnalas	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
4673	Žurnalas	Barrieu M, Chennell P, Yessaad M, Bouattour Y, Wasiak M, Jouannet M, Le Basle Y, Sautou V. Physicochemical Stability of a Novel Tacrolimus Ophtalmic Formulation for the Treatment of Ophtalmic Inflammatory Diseases. Pharmaceutics 2022 ;14,1:118

Mentions Légales